ping an-乐鱼官方网站在线登陆入口

scientific research team

nanjing changao pharmaceutical science and technology co., limited

it’s our r&d center, located in nanjing economic technology development zone. established in 1999, it is a key high-tech enterprise under the national torch program, mainly engaged in pre-clinical and clinical research of drugs. the company focuses on strengthening the construction of technological innovation system and has set up technical platforms such as “jiangsu anti-infective drugs engineering technology research center” and “jiangsu xingang innovative drug formulation research service platform”. after more than twenty years of efforts and continuous investment, the company has established a perfect technological innovation system and strong r&d technical strength.

the company attaches importance to innovation, research and development and intellectual property protection, and has developed a medium- and long-term strategic plan for the development of intellectual property rights to enhance the core competitiveness of the enterprise and promote the rapid development of the company. the company now has innovative drugs with independent intellectual property rights in clinical practice and has successfully conducted technology transfer.

r&d strategy

the company is committed to growing into a first-class drug discovery company aiming at four key areas of drug research and development.four areas：
anti-drug resistant infection drugs[anti-drug resistant bacteria; anti-mdr, xdr tb drugs]
metabolic system drugs[antidiabetic]
circulatory system drugs[antihyperlipidemic; antihypertensive]
digestive system drugs[peptic ulcer; protease inhibitors]

product r&d strategy

three core development strategies: building technology platforms; developing innovative drugs; and developing generic drugs.

cooperative research bases

there are currently about 200 nmpa-approved phase i-iv clinical bases, and c&o has established good relationships with 120 of them

technology exterior science environment

nanjing changao pharmaceutical science and technology co., limited, covering an area of more than 26,000 m2, is mainly engaged in preclinical and clinical research, registration and industrialization services for pharmaceutical products.

scientific payoffs

s/n	indications	r&d phase
1	antibiotics	clinical approval received
2	anti-tb	clinical approval received
3	anti-diabetes	clinical approval received
4	anti-diabetes	clinical approval received

● more than 140 invention patents have been applied to the cnipa, including nearly 52 granted

● 13 international patents have been applied for, including 8 patents granted abroad

● protection of trademarks has also been strengthened, with more than 200 trademark registrations being filed or pending

● 105 new drug certificates and production approvals have been received

● 29 industrialized projects have been implemented by nanjing chang ao pharmaceutical co., limited

● there are 11 provincial high-tech products

● the output value of these products has totaled over ten billion yuan according to statistics

● there are 4 class 1 innovative drugs with independent intellectual property rights under development

● there are more than 10 new drugs in categories 2-5

undertake 10 national-level science and technology projects

project no.	project category	year of project
1	the “12th five-year”plan of “significant new drug creation” science and technology major project	2015
2		2013
3		2011
4		2010
5	the “11th five-year” plan of “significant new drug creation” science and technology major project	2009
6		2009
7		2009
8		2009
9	national small and medium enterprise innovation fund project	2005
10	national 863 projects	2004

undertake 14 science and technology projects of jiangsu province

project no	project category	year of project
1	special funding projects for the transformation of scientific and technological achievements in jiangsu province	2011
2	jiangsu provincial science and technology support program	2010
3	jiangsu provincial science and technology public service platform project	2010
4	jiangsu provincial enterprise academician workstation project	2009
5	jiangsu provincial engineering technology research center project	2008
6	jiangsu provincial natural science foundation program	2008
……

undertake 9 science and technology programs of nanjing

project no.	project category	year of project
1	nanjing high-tech industrialization project	2013
2	nanjing high-tech industrialization project	2011
3	nanjing intellectual property strategy promotion plan	2011
4	nanjing high-tech industrialization project	2010
5	nanjing engineering technology research and entrepreneurship center project	2008
6	nanjing infrastructure construction plan	2007
……

undertake 4 science and technology programs of shanghai

project no.	project category	year of project
1	science and technology innovation action plan	2014
2		2010
3		2009
4	technology innovation fund project for small and medium-sized technology-based enterprises	2008

qualification honor

certified as a high-tech enterprise under the national torch plan

laboratory accreditation certificate

rated as a nanjing intellectual property demonstration enterprise

high-tech enterprise certificate

research service platform

druggability research service platform for innovative drugs in xingang, jiangsu province

it is a service platform for “druggability research of innovative drugs” jointly built by nanjing changao pharmaceutical science and technology co., limited with the cooperation of the university and enterprises against other competitors to seize the high ground, one of the key science and technology innovation platforms in jiangsu, located in national nanjing economic technology development zone, covering a total area of 10,000 m2. the service center has more than 40 senior specialists in multiple disciplines and fields, such as drug analysis, drug synthesis, drug preparation, clinical research, pharmacology and pharmacogenesis, including 1 with a doctorate degree, 19 with a master’s degree and 22 with a bachelor’s degree, forming a highly competitive scientific research team.

the service platform mainly focuses on tumor, metabolic diseases, neurodegenerative diseases, cardiovascular diseases and other harmful diseases, and carries out systematic target research and drug activity discovery research, which improves the efficiency of drug effectiveness evaluation and enriches the information content of drug activity discovery, while significantly reducing the comprehensive cost of drug development. we have been active to introduce foreign advanced science and technology and management experience, which in combination with the advantages of china’s drug development helps create a new path of new drug development in china through the innovation and reinvention of science and technology. this platform covers all procedures of new drug development, including early drug discovery, preclinical drug evaluation, preclinical research, clinical positioning and clinical research organization and monitoring, providing services related to innovative drug development research for small and medium-sized enterprises, research institutes and universities in our province and even in china, and helping them to integrate resources and promote the development and industrialization process of innovative drugs.

the technical services provided by the platform help us to realize the docking of drug research and industrialization, reduce the risk of clinical and marketing, conduct all-round evaluation and systematic research from dimensions such as drug discovery, efficacy, metabolism and toxicity risk, reduce the risk of new drug development, and improve the drug success and the utilization of resources of the whole r&d system. the platform has carried out 6 compounds in all stages of drug discovery, 7 external service projects, and obtained more than 10 million yuan in technical service income; 4 projects have been supported by the special fund for national “major new drug creation” so far.

services

improve the design and synthesis of lead compounds from multiple perspectives and establish a library of lead compounds;
expand the new drug screening resource sample bank and biological cell bank, absorb new techniques for drug activity discovery, and conduct in-depth drug activity discovery research;
build new multiple activity discovery models and conduct in-depth drug effectiveness studies;
establish in vitro absorption activity discovery models applicable to high throughput, and conduct in-depth in vivo and in vitro metabolic behavior studies;
build toxicity research platform technology, metabolic toxicity evaluation platform technology and unique adme/t evaluation system, to carry out in-depth toxicity-related hazard studies;
systematize and standardize clinical positioning and the organization and monitoring of clinical studies;
carry out pharmacoeconomic evaluation;
carry out professional talent training and team building for innovative drug development research.

main services currently offered to the public include:

address： 1 hengfei road, nanjing economic technology development zone, nanjing
tel：025-86912198 025-86912195
fax：025-83254455
contact：wangya@changao.com
postal code：210038